The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Safety and efficacy of venetoclax-based regimens for AML
Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, outlines the safety and efficacy of venetoclax-based regimens for acute myeloid leukemia (AML). Specifically, Dr Žučenka talks on special considerations that ought to be made when using the drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
